Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 2
2009 2
2010 2
2012 4
2013 5
2014 2
2015 2
2016 1
2017 4
2018 2
2019 6
2020 3
2021 3
2022 5
2023 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of intravenous imatinib in COVID-19 ARDS: a randomized, double-blind, placebo-controlled clinical trial.
Atmowihardjo LN, Schippers JR, Duijvelaar E, Bartelink IH, Bet PM, Swart NEL, van Rein N, Purdy K, Cavalla D, McElroy A, Fritchley S, Vonk Noordegraaf A, Endeman H, van Velzen P, Koopmans M, Bogaard HJ, Heunks L, Juffermans N, Schultz MJ, Tuinman PR, Bos LDJ, Aman J. Atmowihardjo LN, et al. Among authors: bartelink ih. Crit Care. 2023 Jun 8;27(1):226. doi: 10.1186/s13054-023-04516-4. Crit Care. 2023. PMID: 37291677 Free PMC article. Clinical Trial.
Pharmacokinetics and pharmacodynamics of imatinib for optimal drug repurposing from cancer to COVID-19.
Baalbaki N, Duijvelaar E, Said MM, Schippers J, Bet PM, Twisk J, Fritchley S, Longo C, Mahmoud K, Maitland-van der Zee AH, Bogaard HJ, Swart EL, Aman J, Bartelink IH. Baalbaki N, et al. Among authors: bartelink ih. Eur J Pharm Sci. 2023 May 1;184:106418. doi: 10.1016/j.ejps.2023.106418. Epub 2023 Mar 2. Eur J Pharm Sci. 2023. PMID: 36870577 Free PMC article. Clinical Trial.
Optimizing Antiviral Dosing for HSV and CMV Treatment in Immunocompromised Patients.
Huntjens DW, Dijkstra JA, Verwiel LN, Slijkhuis M, Elbers P, Welkers MRA, Veldkamp AI, Kuijvenhoven MA, de Leeuw DC, Abdullah-Koolmees H, Kuipers MT, Bartelink IH. Huntjens DW, et al. Among authors: bartelink ih. Pharmaceutics. 2023 Jan 3;15(1):163. doi: 10.3390/pharmaceutics15010163. Pharmaceutics. 2023. PMID: 36678792 Free PMC article. Review.
Pharmacological Optimization of PSMA-Based Radioligand Therapy.
van der Gaag S, Bartelink IH, Vis AN, Burchell GL, Oprea-Lager DE, Hendrikse H. van der Gaag S, et al. Among authors: bartelink ih. Biomedicines. 2022 Nov 23;10(12):3020. doi: 10.3390/biomedicines10123020. Biomedicines. 2022. PMID: 36551776 Free PMC article. Review.
Relationship between Biodistribution and Tracer Kinetics of 11C-Erlotinib, 18F-Afatinib and 11C-Osimertinib and Image Quality Evaluation Using Pharmacokinetic/Pharmacodynamic Analysis in Advanced Stage Non-Small Cell Lung Cancer Patients.
van de Stadt EA, Yaqub M, Schuit RC, Bartelink IH, Leeuwerik AF, Schwarte LA, de Langen AJ, Hendrikse H, Bahce I. van de Stadt EA, et al. Among authors: bartelink ih. Diagnostics (Basel). 2022 Apr 1;12(4):883. doi: 10.3390/diagnostics12040883. Diagnostics (Basel). 2022. PMID: 35453931 Free PMC article.
The INVENT COVID trial: a structured protocol for a randomized controlled trial investigating the efficacy and safety of intravenous imatinib mesylate (Impentri®) in subjects with acute respiratory distress syndrome induced by COVID-19.
Atmowihardjo L, Schippers JR, Bartelink IH, Bet PM, van Rein N, Purdy K, Cavalla D, Comberiati V, McElroy A, Snape SD, Bogaard HJ, Heunks L, Juffermans N, Schultz M, Tuinman PR, Bos LDJ, Aman J. Atmowihardjo L, et al. Among authors: bartelink ih. Trials. 2022 Feb 16;23(1):158. doi: 10.1186/s13063-022-06055-9. Trials. 2022. PMID: 35172891 Free PMC article.
43 results